Ionis Pharmaceuticals

First targeted therapy for rare genetic ALS succeeds in Phase 3 trial

Ionis Pharmaceuticals and Otsuka Pharmaceutical announced on Tuesday that ulefnersen, an investigational RNA-targeted therapy, met the primary endpoint of the Phase III FUSION trial in patients with a rare genetic form of amyotrophic lateral sclerosis, marking a first for this…

Novartis shares slide after cholesterol drug fails trial

Shares of Novartis fell as much as 3.6% on Monday after the Swiss pharmaceutical giant disclosed that its experimental cholesterol drug pelacarsen failed to demonstrate a meaningful reduction in cardiovascular events compared to a placebo in a late-stage clinical trial,…